TENAYA THERAPEUTICS INC (TNYA) Stock Price, Quote, News and Overview
NASDAQ:TNYA - Nasdaq - US87990A1060 - Common Stock - Currency: USD
TNYA Quote, Performance and Key Statistics
0.6338
+0.09 (+17.37%)
The current stock price of TNYA is 0.6338 USD. In the past month the price increased by 43.85%. In the past year, price decreased by -82.59%.
TNYA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.48 | 335.32B | ||
| AMGN | AMGEN INC | 13.99 | 156.11B | ||
| GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
| ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| NTRA | NATERA INC | N/A | 22.36B | ||
| BIIB | BIOGEN INC | 8.42 | 19.51B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Related stock screener links
About TNYA
Company Profile
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. The company is headquartered in South San Francisco, California and currently employs 97 full-time employees. The company went IPO on 2021-07-30. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
Company Info
TENAYA THERAPEUTICS INC
171 Oyster Point Blvd., Suite 500
South San Francisco CALIFORNIA US
CEO: Faraz Ali
Employees: 140
Phone: 14158652066
TENAYA THERAPEUTICS INC / TNYA FAQ
What is the stock price of TENAYA THERAPEUTICS INC today?
The current stock price of TNYA is 0.6338 USD. The price increased by 17.37% in the last trading session.
What is the ticker symbol for TENAYA THERAPEUTICS INC stock?
The exchange symbol of TENAYA THERAPEUTICS INC is TNYA and it is listed on the Nasdaq exchange.
On which exchange is TNYA stock listed?
TNYA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TENAYA THERAPEUTICS INC stock?
15 analysts have analysed TNYA and the average price target is 10.35 USD. This implies a price increase of 1532.34% is expected in the next year compared to the current price of 0.6338. Check the TENAYA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TENAYA THERAPEUTICS INC worth?
TENAYA THERAPEUTICS INC (TNYA) has a market capitalization of 103.10M USD. This makes TNYA a Micro Cap stock.
How many employees does TENAYA THERAPEUTICS INC have?
TENAYA THERAPEUTICS INC (TNYA) currently has 140 employees.
What are the support and resistance levels for TENAYA THERAPEUTICS INC (TNYA) stock?
TENAYA THERAPEUTICS INC (TNYA) has a support level at 0.62. Check the full technical report for a detailed analysis of TNYA support and resistance levels.
Should I buy TENAYA THERAPEUTICS INC (TNYA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TNYA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TNYA, evaluating the profitability, health, valuation and growth aspects
- TENAYA THERAPEUTICS INC (TNYA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TENAYA THERAPEUTICS INC (TNYA) Sales and EPS estimates to see what analysts future expectations are.
- TENAYA THERAPEUTICS INC (TNYA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TENAYA THERAPEUTICS INC (TNYA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TENAYA THERAPEUTICS INC (TNYA) Stock Chart to make your own analysis
- TENAYA THERAPEUTICS INC (TNYA) Latest news and press-releases to stay up to date.
Does TENAYA THERAPEUTICS INC (TNYA) stock pay dividends?
TNYA does not pay a dividend.
What is the Price/Earnings (PE) ratio of TENAYA THERAPEUTICS INC (TNYA)?
TENAYA THERAPEUTICS INC (TNYA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.16).
What is the Short Interest ratio of TENAYA THERAPEUTICS INC (TNYA) stock?
The outstanding short interest for TENAYA THERAPEUTICS INC (TNYA) is 7.55% of its float. Check the ownership tab for more information on the TNYA short interest.
TNYA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TNYA. When comparing the yearly performance of all stocks, TNYA is a bad performer in the overall market: 85.72% of all stocks are doing better.
TNYA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TNYA. TNYA has a great financial health rating, but its profitability evaluates not so good.
TNYA Financial Highlights
Over the last trailing twelve months TNYA reported a non-GAAP Earnings per Share(EPS) of -1.16. The EPS increased by 29.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.47% | ||
| ROE | -88.58% | ||
| Debt/Equity | 0 |
TNYA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to TNYA. The Buy consensus is the average rating of analysts ratings from 15 analysts.